Featured Research

from universities, journals, and other organizations

First step to new therapy for chronic bowel disease

Date:
August 5, 2010
Source:
VIB
Summary:
Scientists have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs.

Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University (UGent) have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs.

Chronic bowel inflammation

Inflammation is a normal protective reaction against tissue damage and infection. This immune response is very specific and only possible after a whole cascade of signals. Sometimes, however, something goes awry in the chain of reactions, leading to an out-of-control inflammation process and possibly undesirable responses against endogenous substances. Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract. Hence, reining in the runaway immune system would seem to be the obvious treatment for these diseases. But this requires a thorough knowledge of the whole process.

TNF, NF-κB and A20

The NF-κB protein plays a critical role in the inflammatory response and is activated by e.g. TNF, which is produced by the white blood cells and acts as a kind of messenger molecule between multiple cell types. This leads in the cell to the production of e.g. A20, a protein that shuts down NF-κB activation and is able to prevent cell death.

A20, new therapeutic target

To identify the physiological role of A20 protein, Lars Vereecke and his colleagues, under the leadership of Geert van Loo and Rudi Beyaert, studied mice whose intestinal epithelial cells (cells that line the intestinal wall) were incapable of producing A20 protein. Their experiments showed that the intestinal epithelial cells of these mice were very sensitive to TNF-induced apoptosis, which in turn made them highly susceptible to developing chronic bowel inflammation. When intestinal epithelium breaks down, bacteria have a chance to penetrate the intestinal tissue, which will trigger a systemic inflammatory response.

In a normal or healthy environment, the role of A20 protein is quite limited. It mainly plays a protective role in the presence of intestinal damage or inflammation. This study confirms the results of a genome-wide analysis, involving a large number of patients, which showed that defects in A20 can play a role in the development of Crohn's disease. This makes A20 protein a promising target for the development of new drugs to treat chronic inflammatory bowel disease.


Story Source:

The above story is based on materials provided by VIB. Note: Materials may be edited for content and length.


Journal Reference:

  1. L. Vereecke, M. Sze, C. M. Guire, B. Rogiers, Y. Chu, M. Schmidt-Supprian, M. Pasparakis, R. Beyaert, G. van Loo. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. Journal of Experimental Medicine, 2010; 207 (7): 1513 DOI: 10.1084/jem.20092474

Cite This Page:

VIB. "First step to new therapy for chronic bowel disease." ScienceDaily. ScienceDaily, 5 August 2010. <www.sciencedaily.com/releases/2010/07/100705081202.htm>.
VIB. (2010, August 5). First step to new therapy for chronic bowel disease. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2010/07/100705081202.htm
VIB. "First step to new therapy for chronic bowel disease." ScienceDaily. www.sciencedaily.com/releases/2010/07/100705081202.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins